



Bal Pharma Limited

CIN # L85110KA1987PLC008368

To,
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

11.08.2014

Dear Sir,

Sub : Out Come of the Board Meeting.


As already informed to the exchanges, the Board of Directors of the Company has met today and *inter alia* transacted the following business,


1. Taken on record and approved the Un-audited financial results of the Company for the quarter ended 30.06.2014. A copy of the financials along with the limited review report issued by the statutory auditors is enclosed with this communication.
2. Proposed to issue 13,00,000 securities on preferential basis to certain strategic investors who have expressed their interest in investing in the Company, which is subject to the approval of the members at the ensuing Annual General Meeting of the Company.

Please take this intimation on record.

Thanking You.

For Bal Pharma Limited


Shailesh Siroya
Managing Director.



Intertek



014

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : balpharma@vsnl.com Website : www.balpharma.com

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bangalore - 560 099. Ph: 41570813 / 19 Fax: 41570820

BAL PHARMA LIMITED
 Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2014
 CIN #: L85110KA1987PLC008368, URL : www.balpharma.com, Email ID : secretarial@balpharma.com


(' in Lakhs)


Sr. No:	Particulars	Quarter Ended			(in Lakhs)
		30.06.2014	31.03.2014	30.06.2013	31.03.2014
		Unaudited			Audited
	Part-1				
1	Net Sales/Income from operations (Net of Excise Duty)	4,144.60	4,662.07	3,676.16	17,341.40
	Other Operating Income	89.43	245.14	94.05	545.80
	Net Income from Sales/Services	4,234.03	4,907.21	3,770.21	17,887.20
2	Expenditure				
	a) Increase/decrease in stock in trade and WIP	(192.75)	107.07	(58.88)	95.94
	b) Consumption of Raw Materials/ Packing Material	2,264.55	2,435.20	1,778.68	8,911.84
	c) Purchase of Stock in Trade	106.50	144.04	74.57	515.41
	d)Employee Cost	764.33	744.86	655.30	2,812.36
	e) Depreciation and amortisation expenses	112.14	101.72	152.26	473.97
	f) Other Expenditure	890.95	1,035.27	877.96	3,763.97
	g) Total	3,945.72	4,568.16	3,479.89	16,573.49
3	Profit from Operations before other Income, interest and Exceptional items(1-2)	288.31	339.05	290.32	1,313.71
4	Other Non-operating Income	6.03	37.20	7.90	64.63
5	Profit before Interest and Exceptional items (3+4)	294.34	376.25	298.22	1,378.34
6	Finance Costs	162.73	181.85	181.99	715.74
7	Profit after Interest but before Exceptional items	131.61	194.40	116.23	662.60
8	Exceptional items	-	-	-	-
9	Profit/Loss from ordinary activities Before Tax (7-8)	131.61	194.40	116.23	662.60
10	Tax expenses	33.20	58.63	24.78	155.37
11	Net Profit /Loss from ordinary Activities after Tax	98.41	135.77	91.45	507.23
12	Extra ordinary items	-	-	-	-
13	Net Profit / Loss for the period	98.41	135.77	91.45	507.23
14	Paid-up Equity Share capital(face value of Rs 10 each)	1,287.24	1,111.14	1,057.36	1,111.14
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				3,283.79
16	EPS (in Rs.)				
	a) Basic	0.78	1.25	0.86	4.77
	b) Diluted	0.78	1.21	0.86	4.60
	Part II				
	Particulars of Share Holding				
17	Public shareholding				
	- Number of Shares	6,586,570	5,142,086	5,142,086	5,142,086
	- Percentage of shareholding	51.17	46.28	48.63	46.28
18	Promoters & Promoter group Shareholding				
	a) Pledged / Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of shareholding	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	6,285,802	5,969,302	5,431,538	5,969,302
	- Percentage of shareholding	48.83	53.72	51.37	53.72

Notes:

- The above Un-audited financials results as reviewed by the Audit Committee were approved by the Board of Directors at its meeting held on 11.08.2014
- Statutory Auditors have conducted limited review on the Un-Audited financial results for the quarter ended 30.06.2014.
- Investor grievances : Outstanding at the beginning of the quarter : Nil, received during the quarter : 2, resolved during the quarter 2: pending at the end of the quarter : Nil.
- With reference to the Limited Review Report Dated 11.08.2014 by statutory Auditors on Depreciation provision : With effect from 1st April 2014, Companies Act,2013 prescribes for the useful lives of various assets. Pending determination of various useful lives of assets, the Company continues to provide depreciation at the rates prescribed hitherto.
- Previous year figures were regrouped/rearranged to conform to the classification of current year.
- As the Company deals with single product i.e pharmaceuticals, segment wise figures are not furnished.

Bangalore
11.08.2014

By order of the Board of Directors
For Bal Pharma limited

Shailesh Siroya
Managing Director





T D JAIN AND D I SAKARIA

CHARTERED ACCOUNTANTS

CA T.D. JAIN B.Com., F.C.A.
CA DHANPAL I SAKARIA
B.Com., F.C.A.

34, Keshava Nivas, 3rd Floor
First Main, Gandhinagar
Bangalore-560 009
Phone : 22356136, 22356137
Telefax : 080-22356136
E-mail : ostawalljain@gmail.com

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of Bal Pharma Limited having its registered office at 21 & 22, Bommasandra Industrial Area, Hosur Road, Bangalore - 560099 for the quarter ended on 30 June, 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute Of Chartered Accountants Of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

In the aforesaid statement,

The Depreciation is provided as per Schedule XIV of the companies act, 1936, and not as per schedule II of the companies act, 2013.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s T D JAIN AND D I SAKARIA
Chartered Accountants

T D Jain
Partner
M.No.012034

Place: Bangalore
Date: 11 August 2014